Stockscreener 앱 받기
21.03
3.24%
0.66
시간 외 거래:
21.03
전일 마감가:
$20.37
열려 있는:
$20.725
하루 거래량:
1.05M
Relative Volume:
1.85
시가총액:
$617.87M
수익:
$17.16M
순이익/손실:
$-163.62M
주가수익비율:
-3.4589
EPS:
-6.08
순현금흐름:
$-121.61M
1주 성능:
-14.82%
1개월 성능:
-13.28%
6개월 성능:
+44.24%
1년 성능:
-37.39%
1일 변동 폭
$19.20
$21.24
1주일 범위
$19.20
$25.61
52주 변동 폭
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
21.03 | 662.24M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
AnaptysBio Reports Q2 2025 Financial Results and Updates - TipRanks
Wedbush Forecasts AnaptysBio's Q4 Earnings (NASDAQ:ANAB) - MarketBeat
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - 富途牛牛
AnaptysBio (NASDAQ:ANAB) Stock Price Down 9.8%Here's Why - MarketBeat
Wedbush Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio's Promising Pipeline and Financial Stability Support Buy Rating - AInvest
AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating - TipRanks
BIT Capital GmbH Purchases Shares of 25,422 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
DCF Advisers LLC Invests $648,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth - AInvest
Wedbush Raises Price Target on AnaptysBio to $45 From $40, Keeps Outperform Rating - MarketScreener
AnaptysBio (ANAB) Target Price Raised by Wedbush | ANAB Stock Ne - GuruFocus
AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 18c - StreetInsider
AnaptysBio (ANAB) Q2 Revenue Jumps 103% - The Globe and Mail
AnaptysBio earnings beat by $0.18, revenue topped estimates - Investing.com Canada
AnaptysBio reports Q2 EPS ($1.34), consensus ($1.58) - TipRanks
AnaptysBio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
AnaptysBio Reports Positive Phase 2b Data for Rosnilimab in Rheumatoid Arthritis and Completes Enrollment for Ulcerative Colitis Trial - Quiver Quantitative
Anaptys Delivers Strong RA Trial Results and Eyes $75M Milestone as Pipeline Advances - Stock Titan
Palmoplantar Pustulosis Clinical Trials, Companies, - openPR.com
Palmoplantar Pustulosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., AnaptysBio, Inc., Boeh - Barchart.com
AnaptysBio Inc. Crosses 200 Day MA — Signal or NoiseProfit Focused Stock Screener Results Released - metal.it
Skandinaviska Enskilda Banken AB publ Purchases New Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
How many analysts rate AnaptysBio Inc. as a “Buy”Invest confidently with professional advice - Jammu Links News
Is AnaptysBio Inc. stock overvalued or undervaluedSuperior investment outcomes - Jammu Links News
What is AnaptysBio Inc. company’s growth strategyMaximize portfolio growth with expert advice - Jammu Links News
What institutional investors are buying AnaptysBio Inc. stockPhenomenal wealth increase - Jammu Links News
How does AnaptysBio Inc. generate profit in a changing economyHigh-impact stock picks - Jammu Links News
What are AnaptysBio Inc. company’s key revenue driversFree Buy/Sell Signal Notifications - Jammu Links News
AnaptysBio Inc. Stock Analysis and ForecastRapidly growing investment returns - Jammu Links News
When is AnaptysBio Inc. stock expected to show significant growthAchieve consistent double-digit growth rates - Jammu Links News
How does AnaptysBio Inc. compare to its industry peersBuild a winning portfolio with smart picks - Jammu Links News
What makes AnaptysBio Inc. stock price move sharplyUnlock exclusive stock market insights - Jammu Links News
Is it the right time to buy AnaptysBio Inc. stockTriple returns potential - Jammu Links News
What catalysts could drive AnaptysBio Inc. stock higher in 2025Identify undervalued stocks ready to soar - Jammu Links News
Why is AnaptysBio Inc. stock attracting strong analyst attentionInvest smarter with actionable market insights - Jammu Links News
AnaptysBio Faces Critical Risk: Potential Impact on Operations and Investor Confidence - The Globe and Mail
Price Channel Expanding on AnaptysBio Inc.’s ChartCommunity Verified Stock Suggestions Drive Volume - metal.it
AnaptysBio's New Risk: Impact on Operations and Investor Confidence - AInvest
AnaptysBio (ANAB) Projected to Post Earnings on Monday - MarketBeat
Corton Capital Inc. Buys Shares of 10,699 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):